Thinking of Buying Cytokinetics (CYTK)? Here's What You Need to Know.

Shares of Healthcare sector company Cytokinetics moved 5.8% today, and are now trading at a price of $38.08. The mid-cap stock's daily volume was 477,139 compared to its average volume of 1,101,658. The S&P 500 index returned a -0.2% performance.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is based in South San Francisco and has 253 full time employees. Its market capitalization is $3,603,548,672.

13 analysts are following Cytokinetics and have set target prices ranging from $55 to $82 per share. On average, they have given the company a rating of buy. At today's prices, CYTK is trading -44.31% away from its average analyst target price of $68.38 per share.

Over the last year, CYTK shares have gone down by -0.3%, which represents a difference of 15.6% when compared to the S&P 500. The stock's 52 week high is $55.8 per share and its 52 week low is $29.26. Cytokinetics has averaged free cash flows of $-97,283,250.0 over the last four years, with a mean growth rate of -2956.3%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.